Disodium Etidronate Therapy for Dystrophic Cutaneous Calcification
Steven Fisher Rabens
Abstract
Steven Fisher Rabens
Abstract
A patient with extensive disabling dystrophic cutaneous calcification and possible scleroderma was treated with orally administered doses of a diphosphonate known as disodium etidronate. This course of therapy seemed to arrest and partially reverse the progression of the calcifying process. Some deep deposits were then seen to dissipate and be partially reabsorbed, while some small superficial depcific deposits were halted in most areas while the patient was under therapy. Clinically, pain was reduced, recurrent abscess formation ceased, and joint mobility was improved.
OpenAlex reports 53 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
A patient with extensive disabling dystrophic cutaneous calcification and possible scleroderma was treated with orally administered doses of a diphosphonate known as disodium etidronate. This course of therapy seemed to arrest and partially reverse the progression of the calcifying process. Some deep deposits were then seen to dissipate and be partially reabsorbed, while some small superficial depcific deposits were halted in most areas while the patient was under therapy. Clinically, pain was reduced, recurrent abscess formation ceased, and joint mobility was improved.
Key concepts: Medicine, Dystrophic calcification, Calcification, Calcinosis, Scleroderma (fungus), Dermatology, Surgery, Pathology